Exelixis
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
EXEL News
Exelixis recently announced detailed results from its phase 3 STELLAR-303 trial, showing that the combination of zanzalintinib and atezolizumab achieved a 20% r...
Morgan Stanley lowered the firm’s price target on Exelixis (EXEL) to $44 from $50 and keeps an Overweight rating on the shares after company presented detailed...
Leerink upgraded Exelixis (EXEL) to Outperform from Market Perform with a $48 price target Published first on TheFly – the ultimate source for real-time, marke...
Analyst ratings
62%
of 21 ratingsMore EXEL News
The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persiste...
...
Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial. The trial evaluated...
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday. Shares of Olema Pharmaceuticals Inc (NASDAQ:OLMA) fell 18.3% t...
Exelixis (EXEL) announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX versus placebo in patients with previously...
Exelixis (EXEL) just shared new results from a subgroup analysis of its phase 3 CABINET trial. The study showed that CABOMETYX substantially reduced disease pro...